Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in type II diabetes mellitus

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 3, 2007, Pages 275-281

  Berria, R ^a,b   Glass, L ^a   Mahankali, A ^a   Miyazaki, Y ^a   Monroy, A ^a   De Filippis, E ^a   Cusi, K ^a   Cersosimo, E ^a   DeFronzo, R A ^a   Gastaldelli, A ^a,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PIOGLITAZONE; PLACEBO;

ADULT; ANEMIA; ARTICLE; BLOOD CELL COUNT; BODY FAT; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR FLUID; FEMALE; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT; TOTAL BODY WATER; WEIGHT GAIN;

ADULT; BLOOD CELL COUNT; BLOOD GLUCOSE; BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY WATER; BODY WEIGHT; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMATOCRIT; HEMODILUTION; HEMOGLOBIN A, GLYCOSYLATED; HEMOGLOBINS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 34547882402     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100146     Document Type: Article

References (43)

1. Stumvoll, M. & Hu, H. Glitazones clinical effects and molecular mechanisms. Ann. Med. 34, 217-224 (2002).
2. Research Triangle Park, NC, May 2002 Avandia [package insert].
3. Lincolnshire Illinois: Takeda Pharmaceuticals America, Inc. and Indianapolis, IN: Eli Lilly, and Company, August 2004 Actos.
4. Tang, W., Francis, G., Hoogwerf, B. & Young, J. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J. Am. Coll. Cardiol. 41, 1394-1398 (2003).
5. Hollemberg, N. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am. J. Med. 115, 111S-115S (2003).
6. Miyazaki, Y. et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 87, 2784-2791 (2002).
7. Kelly, I., Han, T., Walsh, K. & Lean, M. Effect of thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22, 288-293 (1999).
8. Barbieri, M., Ragno, E., Benvenuti, E., Zito, G.A., Corsi, A. & Ferrucci, L.G.P. New aspects of the insulin resistance syndrome: impact on haematological parameters. Diabetologia 44, 1232-1237 (2001).
9. Catalano, C. et al. Reciprocal association between insulin sensitivity and the haematocrit in man. Eur. J. Clin. Invest. 27, 634-637 (1997).
10. Miyagawa, S.-I., Kobayashi, M., Konishi, N., Sato, T. & Ueda, K. Insulin and insulin-like growth factor I support the proliferation of erythroid progenitor cells in bone marrow through the sharing of receptors. Br. J. Hematol. 109, 555-562 (2000).
11. Chilcott, J., Tappenden, P. & Jones, M. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin. Ther. 23, 1792-1823 (2001).
12. Kuzuya, T. et al. A pilot clinical trial of a new oral hypoglycemic agent CS-045, in patients with non-insulin dependent diabetes mellitus. Diabetes Res. Clin. Pract. 11, 147-153 (1991).
13. Kinley, J. & Urquhart, R. Effect of pioglitazone on water volumes in patients with type 2 diabetes. Diabetologia 48, A281 (2005).
14. Ellis, K.J. & Wong, W.W. Human hydrometry: comparison of multifrequency bioelectrical impedance with 2H2O and bromine dilution. J. Appl. Physiol. 85, 1056-1062 (1998).
15. Scheltinga, M.R., Jacobs, D.O., Kimbrough, T.D. & Wilmore, D. Alterations in body fluid content can be detected by bioelectrical impedance analysis. J. Surg. Res. 50, 461-468 (1991).
16. Van Marken Lichtenbelt, W.D.,Westerterp, K.R. & Wouters, L. Deuterium dilution as a method for determining total body water: effect of test protocol and sampling time. Brit. J. Nutr. 72, 491-497 (1994).
17. Berria, R. et al. Reduction in hematocrit following pioglitazone treatment is correlated with decreased plasma-free testosterone, not hemodilution, in women with polycystic ovarian syndrome. Clin. Pharmacol. Ther. 80, 105-114 (2006).
18. Basu, A., Jensen, M.D., McCann, F., Mukhopadhyay, D., Joyner, M.J. & Rizza, R.A. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 29, 510-514 (2006).
19. Schoeller, D.A. & Santen, E.V. Measurement of energy expenditure in humans by doubly labeled water method. J. Appl. Physiol. 53, 955-959 (1982).
20. 18O method in the elderly. J. Appl. Physiol. 92, 1036-1044 (2002).
21. Jankowski, C.M., Sonko, B.J., Gozansky, W.S. & Kohrt, W. Deuterium dilution: the time course of 2H enrichment in saliva, urine and serum. Clin. Chem. 50, 1699-1701 (2004).
22. Schloerb, P.R., Friis-Hansen, B.J., Edelman, I.S., Solomon, A.K. & Moore, F. The measurement of total body water in the human subject by deuterium oxide dilution. J. Clin. Invest. 29, 1296-1310 (1950).
23. Wang, Z.M., Deurenberg, P., Wang, W., Pietrobelli, A., Baumgartner, R.M. & Heymsfield, S. Hydration of fat-free body mass: review and critique of a classic body composition constant. Am. J. Clin. Nutr. 69, 833-841 (1999).
24. Sheng, H.P. & Huggins, R. A review of body composition studies with emphasis on total body water and fat. Am. J. Clin. Nutr. 32, 630-647 (1979).
25. Smith, S.R., De Jonge, L., Volaufova, J., Li, Y., Xie, H. & GA, B. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 54, 24-32 (2005).
26. Yki-Jarvinen, H. Thiazolidinediones. N. Engl. J. Med. 351, 1106-1118 (2004).
27. Akbiyik, F., Ray, D.M., Gettings, K.F., Blumberg, N., Francis, C.W. & Phipps, R.P. Human bone marrow megakaryocytes and platelets express PPARY and PPARY against blunt platelet release of CD40 ligand and thromboxanes. Blood 104, 1361-1368 (2004).
28. Deldar, A., Williams, G. & Stevens, C. Pathogenesis of thiazolidinedione induced hematotoxicity in the dog. Diabetes 42, 179 (1993).
29. Sottile, V., Seuwen, K. & Kneissel, M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif. Tissue Int. 75, 329-337 (2004).
30. Hirase, N. et al. Thiazolidinedione suppresses the expression of erythroid phenotype in erythroleukemia cell line K562. Leukemia Res. 24, 393-400 (2000).
31. Nagasawa, E., Abe, Y., Nishimura, J., Yanase, T., Nawata, H. & Muta, K. Pivotal role of peroxisome proliferator-activated receptor γ (PPARγ) in regulation of erythroid progenitor cell proliferation and differentiation. Exp. Hematology 33, 857-864 (2005).
32. Schlezinger, J.J., Jensen, B.A., Mann, K.K., Ryu, H.-Y. & Sherr, D. Peroxisome proliferator-activated receptor γ-mediated NF-κB activation and apoptosis in pre-B cells. J. Immunol. 169, 6831-6841 (2002).
33. Mudaliar, S. & Henry, R.R. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu. Rev. Med. 52, 25(5) 239-257 (2001).
34. Consoli, A. & Devangelio, E. Thiazolidinediones and inflammation. Lupus 14, 794-797 (2005).
35. Buckingham, R. Thiazolidinediones: pleiotropic drugs with potent anti-inflammatory properties for tissue protection. Hepatol. Res. 33, 167-170 (2005).
36. Gawaz, M., Langer, H. & May, A.E. Platelets in inflammation and atherogenesis. J. Clin. Invest 115, 3378-3384 (2005).
37. DeFronzo, R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med 131, 281-303 (1999).
38. Masuda, S., Chikuma, M. & Sasaki, R. Insulin-like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes. Brain Res. 746, 63-70 (1997).
39. Miyazaki, Y. et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diab. Care 24, 710-719 (2001).
40. Shadid, S. & Jensen, M.D. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 26, 3148-3152 (2003).
41. Lebovitz, H. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab. Res. Rev. 18, S23-S29 (2002).
42. Niemeyer, N. & Janney, L. Thiazolidinedione-induced edema. Pharmacotherapy 22, 924-929 (2002).
43. Hume, R. & Weyers, E. Relationship between total body water and surface area in normal and obese subjects. J. Clin. Pathol. 24, 234-238 (1971).